Explore

Trendline Trendline
FDA's Second Rejection of Replimune's Melanoma Drug RP1 Sparks Strategic Overhaul

FDA's Second Rejection of Replimune's Melanoma Drug RP1 Sparks Strategic Overhaul

FDA's Second Rejection of Replimune's Melanoma Drug RP1 Sparks Strategic Overhaul
Trendline Trendline
Replimune Faces Uncertainty After FDA Rejects Melanoma Drug

Replimune Faces Uncertainty After FDA Rejects Melanoma Drug

Replimune Faces Uncertainty After FDA Rejects Melanoma Drug
Trendline Trendline
FDA Rejects Replimune's Melanoma Therapy for Second Time

FDA Rejects Replimune's Melanoma Therapy for Second Time

FDA Rejects Replimune's Melanoma Therapy for Second Time
Rapid Read Rapid Read
FDA Rejects Replimune's Melanoma Therapy, Impacting Patients and Company

FDA Rejects Replimune's Melanoma Therapy, Impacting Patients and Company

Replimune's advanced melanoma treatment, RP1, has been rejected by the FDA for the second time. The therapy, which combines RP1 with Bristol Myers Squibb's Opdivo, was intended for patients with advanced melanoma who have not responded to anti-PD-1 treatments. The FDA's decision was based on concerns about the trial data, including the inability to distinguish RP1's effects from Opdivo and issues with the patient population size. Replimune has criticized the FDA for inconsistent communication and a fragmented regulatory process, claiming the decision contradicts expert opinions and patient needs. The rejection has led to significant financial and operational impacts for Replimune, including job cuts and reduced manufacturing operations.
Trendline Trendline
Telix Pharmaceuticals Advances in Radiopharmaceuticals with FDA Nod for Brain Cancer Imaging Agent

Telix Pharmaceuticals Advances in Radiopharmaceuticals with FDA Nod for Brain Cancer Imaging Agent

Telix Pharmaceuticals Advances in Radiopharmaceuticals with FDA Nod for Brain Cancer Imaging Agent
Trendline Trendline
FDA's Transparency Policy on Complete Response Letters Enhances Biopharma Accountability

FDA's Transparency Policy on Complete Response Letters Enhances Biopharma Accountability

FDA's Transparency Policy on Complete Response Letters Enhances Biopharma Accountability
Trendline Trendline
Telix Pharmaceuticals Gains FDA Acceptance for Brain Cancer Imaging Agent, Signaling New Revenue Stream

Telix Pharmaceuticals Gains FDA Acceptance for Brain Cancer Imaging Agent, Signaling New Revenue Stream

Telix Pharmaceuticals Gains FDA Acceptance for Brain Cancer Imaging Agent, Signaling New Revenue Stream
Rapid Read Rapid Read
FDA Urges Over 2,200 Sponsors and Researchers to Disclose Clinical Trial Results to Ensure Transparency

FDA Urges Over 2,200 Sponsors and Researchers to Disclose Clinical Trial Results to Ensure Transparency

The U.S. Food and Drug Administration (FDA) has issued reminders to more than 2,200 medical product companies and researchers to comply with the requirement to submit clinical trial results to ClinicalTrials.gov. This action addresses the issue of non-disclosure of trial results, which can lead to significant gaps in the public record and a publication bias that misrepresents the true outcomes of drug development. According to the FDA, 29.6% of studies that are likely subject to mandatory reporting have not submitted results. The agency's reminders, sent on March 30, 2026, aim to encourage voluntary compliance before considering further regulatory actions. The FDA emphasizes the ethical obligation of sponsors to disclose results, regardless of their impact on company share prices, to ensure that clinicians and researchers have access to comprehensive data.
Trendline Trendline
FDA Grants Clearance to Miracell's SMART M-CELL System, Paving Way for U.S. Expansion

FDA Grants Clearance to Miracell's SMART M-CELL System, Paving Way for U.S. Expansion

FDA Grants Clearance to Miracell's SMART M-CELL System, Paving Way for U.S. Expansion
Trendline Trendline
FDA Rejects Replimune's Advanced Melanoma Drug for Second Time, Impacting Biotech Sector

FDA Rejects Replimune's Advanced Melanoma Drug for Second Time, Impacting Biotech Sector

FDA Rejects Replimune's Advanced Melanoma Drug for Second Time, Impacting Biotech Sector
Trendline Trendline
Replimune's Skin Cancer Drug Faces Another FDA Rejection Amid Regulatory Scrutiny

Replimune's Skin Cancer Drug Faces Another FDA Rejection Amid Regulatory Scrutiny

Replimune's Skin Cancer Drug Faces Another FDA Rejection Amid Regulatory Scrutiny
Rapid Read Rapid Read
Former Sen. Ben Sasse Highlights Potential Breakthrough in Pancreatic Cancer Treatment

Former Sen. Ben Sasse Highlights Potential Breakthrough in Pancreatic Cancer Treatment

Former Senator Ben Sasse has brought attention to a potential breakthrough in pancreatic cancer treatment involving a drug called daraxonrasib, developed by Revolution Medicines. Sasse, who was diagnosed with Stage 4 pancreatic cancer, reported a significant reduction in his tumors after taking the drug. The company is preparing to release results from a Phase 3 trial, which could make daraxonrasib the first targeted treatment for pancreatic cancer, a disease with a notoriously low survival rate. The drug targets RAS mutations, which are present in the majority of pancreatic cancer cases. Despite promising results, the drug has side effects, including severe skin rashes, due to its broad activity against RAS proteins throughout the body.